A new approach to the preeclampsia puzzle; MicroRNA-326 in CD4


Journal

Journal of reproductive immunology
ISSN: 1872-7603
Titre abrégé: J Reprod Immunol
Pays: Ireland
ID NLM: 8001906

Informations de publication

Date de publication:
06 2021
Historique:
received: 15 12 2020
revised: 19 03 2021
accepted: 24 03 2021
pubmed: 5 4 2021
medline: 15 12 2021
entrez: 4 4 2021
Statut: ppublish

Résumé

Alongside many complications in understanding the etiology of Preeclampsia (PE), several determinants, such as the imbalanced proportion of anti-angiogenic/proangiogenic T-cell subsets, especially CD4 After sample collection and preparation, CD4 Our results showed that the miRNA-326 expression level increased in CD4 In conclusion, we comprehensively evaluated immunological factors and molecules involved in PE manifestation. Interestingly, the CD4

Sections du résumé

BACKGROUND
Alongside many complications in understanding the etiology of Preeclampsia (PE), several determinants, such as the imbalanced proportion of anti-angiogenic/proangiogenic T-cell subsets, especially CD4
MATERIAL AND METHOD
After sample collection and preparation, CD4
RESULTS
Our results showed that the miRNA-326 expression level increased in CD4
CONCLUSION
In conclusion, we comprehensively evaluated immunological factors and molecules involved in PE manifestation. Interestingly, the CD4

Identifiants

pubmed: 33813342
pii: S0165-0378(21)00047-4
doi: 10.1016/j.jri.2021.103317
pii:
doi:

Substances chimiques

ENG protein, human 0
Endoglin 0
MIRN326 microRNA, human 0
MicroRNAs 0
FLT1 protein, human EC 2.7.10.1
Vascular Endothelial Growth Factor Receptor-1 EC 2.7.10.1

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

103317

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Auteurs

Mohammad Ali Zolfaghari (MA)

Department of Molecular Medicine, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran; Molecular Medicine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Roza Motavalli (R)

Department of Molecular Medicine, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.

Mohammad Sadegh Soltani-Zangbar (MS)

Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Forough Parhizkar (F)

Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Shahla Danaii (S)

Gynecology Department, Eastern Azerbaijan ACECR ART Center, Eastern Azerbaijan Branch of ACECR, Tabriz, Iran.

Leili Aghebati-Maleki (L)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Mohammad Noori (M)

Department of Reproductive Biology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.

Sanam Dolati (S)

Physical Medicine and Rehabilitation Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran.

Majid Ahmadi (M)

Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Hossein Samadi Kafil (H)

Drug Applied Research Center, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.

Farhad Jadidi-Niaragh (F)

Department of Immunology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.

Javad Ahmadian Heris (J)

Department of Allergy and Clinical Immunology, Pediatric Hospital, Tabriz University of Medical Sciences, Tabriz, Iran.

Ata Mahmoodpoor (A)

Department of Anesthesiology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.

Mohammad Saeid Hejazi (MS)

Department of Molecular Medicine, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.

Mehdi Yousefi (M)

Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Immunology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: Yousefime@tbzmed.ac.ir.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH